Colonic toxicity from pancreatins: a contemporary safety issue (Q33545562)

27 July 2017

1 reference

title

Colonic toxicity from pancreatins: a contemporary safety issue (English)

1 reference

27 July 2017

C J Powell

1

1 reference

27 July 2017

language of work or name

English

0 references

publication date

1 March 1999

1 reference

27 July 2017

1 reference

27 July 2017

volume

353

1 reference

27 July 2017

issue

9156

1 reference

27 July 2017

page(s)

911-915

1 reference

Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

High-strength pancreatic enzyme supplements and large-bowel stricture in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

The pathology of fibrosing colonopathy of cystic fibrosis: a study of 12 cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Fibrosing colonopathy in cystic fibrosis: results of a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Extensive pathological changes of the colon in cystic fibrosis and high-strength pancreatic enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Colonic strictures in patients with cystic fibrosis: results of a survey of 114 cystic fibrosis care centers in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Cystic fibrosis-associated colitis and fibrosing colonopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

High-dose pancreatic-enzyme supplements and fibrosing colonopathy in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Progressive pan-colonic fibrosis secondary to oral administration of pancreatic enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

First adult patient with fibrosing colonopathy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Ultrasound studies of the intestinal wall in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Pancreatic enzyme supplementation in cystic fibrosis patients before and after fibrosing colonopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Ethyl acrylate-induced gastric toxicity. I. Effect of single and repetitive dosing.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Ethyl acrylate-induced gastric toxicity. II. Structure-toxicity relationships and mechanism.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Ethyl acrylate-induced gastric toxicity. III. Development and recovery of lesions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

The histopathological and biochemical response of the stomach of male F344/N rats following two weeks of oral dosing with ethyl acrylate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Propionic acid and the phenomenon of rodent forestomach tumorigenesis: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Is fibrosing colonopathy an immune mediated disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Colonic strictures in children with cystic fibrosis on low-strength pancreatic enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Colonic strictures in cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Fibrosing colonopathy in a child on low-dose pancreatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Patterns of use of pancreatic enzyme supplements in fibrosing colonopathy: implications for pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Stated versus actual lipase activity in pancreatic enzyme supplements: implications for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

Energy content of stools in normal healthy controls and patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

High strength pancreatic exocrine enzyme capsules associated with colonic strictures in patients with cystic fibrosis: "more is not necessarily better"

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2898%2902023-6

7 January 2021

10.1016/S0140-6736(98)02023-6

Identifiers

DOI

1 reference

27 July 2017

1 reference